Abstract
Sacubitril/valsartan, an angiotensin receptor/neprilysin inhibitor (ARNi), is one of the newest drug classes with efficacy in improving heart failure (HF) outcomes. We aimed to determine the longitudinal adherence patterns of ARNi among Medicare beneficiaries with HF and to identify factors associated with ARNi adherence.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
